CD34 and breast cancer: Data from single-cell RNA-seq profiling of bone marrow CD34 + cells isolated from either healthy donors (control) (n = 8) or CML patients classified based on European LeukemiaNet into three groups (described in detail in the Methods section): (A) imatinib good response (n = 9); (B) imatinib resistance (n = 9) and (C) pan-TKI resistance with progression into blast crisis (BC) (n = 9) were used.